Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates

• Published in: The Pediatric infectious disease journal Vol. 8; no. 11; p. 759
• Main Authors: Noya, F J, Rench, M A, Courtney, J T, Feldman, S, Baker, C J
• Format: Journal Article
• Language: English
• Published: United States 01.11.1989
• Subjects: Drug Combinations - administration & dosage; Drug Combinations - adverse effects; Drug Combinations - pharmacokinetics; Female; Fibrinolysin - administration & dosage; Fibrinolysin - adverse effects; Fibrinolysin - pharmacokinetics; gamma-Globulins - administration & dosage; gamma-Globulins - adverse effects; gamma-Globulins - pharmacokinetics; Humans; Immunoglobulin G - analysis; Immunoglobulins, Intravenous; Infant, Low Birth Weight - metabolism; Infant, Newborn; Infusions, Intravenous; Male; Prospective Studies; Random Allocation; Regression Analysis
• ISSN: 0891-3668
• DOI: 10.1097/00006454-198911000-00006

We studied the pharmacokinetics of single doses of intravenous immunoglobulin (IVIG) of 1000, 750 and 500 mg/kg administered to 21 neonates with birth weights from 750 to 1500 g. No adverse effects were detected. Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg. Mean peak IgG concentrations in serum were 1826, 1476 and 1257 mg/dl for the large, intermediate and small dose groups, respectively. Mean IgG on post-infusion Days 1 to 28 were similar for the intermediate and small dose groups but were higher in the larger dose group. Both large and intermediate doses achieved larger increases in IgG over preinfusion values (delta IgG) than the small dose. The differences in delta IgG between the large and intermediate doses were less notable. The wide variability observed indicates that individualization of intravenous immunoglobulin dosage will be required in these patients.